Skip to main content
logo
Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.680
+0.220 (6.36%)
At close: Apr 6, 2026, 4:00 PM EDT
3.750
+0.070 (1.90%)
After-hours: Apr 6, 2026, 7:12 PM EDT

Prelude Therapeutics Revenue

In the year 2025, Prelude Therapeutics had annual revenue of $12.14M with 73.43% growth. Prelude Therapeutics had revenue of $5.64M in the quarter ending December 31, 2025, with 41.00% growth.

Revenue (ttm)
$12.14M
Revenue Growth
+73.43%
P/S Ratio
25.02
Revenue / Employee
$153,671
Employees
79
Market Cap
303.73M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202512.14M5.14M73.43%
Dec 31, 20247.00M--
Dec 31, 2023---
Dec 31, 2022---
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
C4 Therapeutics35.95M
Foghorn Therapeutics30.91M
Ovid Therapeutics7.25M
Abeona Therapeutics5.82M
AC Immune4.51M
Silence Therapeutics559.00K
SAB Biotherapeutics114.70K
Adlai Nortye-1.35M
Revenue Rankings

PRLD News

More News